Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Dividend Announcements, Earnings Release Scheduled, and Data Presentations from Clinical Studies - Research Report on Questcor,



  Dividend Announcements, Earnings Release Scheduled, and Data Presentations
 from Clinical Studies - Research Report on Questcor, Regeneron, NPS, Incyte,
                                  and Nektar

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, October 16, 2013

NEW YORK, October 16, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Questcor
Pharmaceuticals, Inc. (NASDAQ: QCOR), Regeneron Pharmaceuticals, Inc. (NASDAQ:
REGN), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Incyte Corporation (NASDAQ:
INCY), and Nektar Therapeutics (NASDAQ: NKTR). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Questcor Pharmaceuticals, Inc. Research Report  

On October 10, 2013, Questcor Pharmaceuticals, Inc.'s (Questcor) Board of
Directors has declared a quarterly cash dividend of $0.30 per share ($1.20 per
share on an annual basis), payable on or about October 30, 2013 to
shareholders of record at the close of business on October 22, 2013. Questcor
reported that the recently announced dividend reflects an increase of $0.05 or
20% QoQ and a 50% YoY. "Our second dividend increase this year reflects our
strong financial performance to date, driven by increasing usage of Acthar
among physicians to treat patients with serious, difficult to treat medical
conditions," said Don M. Bailey, President and CEO of Questcor. "Our business
is generating a growing amount of cash flow, as evidenced by Questcor's $278
million in cash and investments at October 4, 2013. Our cash position includes
$75 million in restricted cash, unchanged from the second quarter 2013. We
remain committed to using our strong cash flow to invest in our business,
including significant investments in R&D, while returning cash to
shareholders. To date we have maintained a payout ratio-dividends paid per
share divided by earnings per share-of approximately 20%." The Full Research
Report on Questcor Pharmaceuticals, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.AnalystsCorner.com/r/full_research_report/a415_QCOR]

--

Regeneron Pharmaceuticals, Inc. Research Report

On October 10, 2013, Regeneron Pharmaceuticals, Inc. (Regeneron) announced
that it will release its Q3 2013 financial and operating results before the US
markets open on Tuesday, November 5, 2013. Regeneron reported that it will
also host a conference call and webcast on the same day at 8:30 a.m. ET.
According to the Company, interested parties may access the call through the
Events and Presentations section of its website, wherein a replay of the call
and its webcast will be available for 30 days. The Full Research Report on
Regeneron Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/8ea7_REGN]

--

NPS Pharmaceuticals, Inc. Research Report

On October 7, 2013, NPS Pharmaceuticals, Inc. (NPS) announced that it
presented findings from REPLACE, its pivotal Phase 3 study of Natpara
(recombinant human parathyroid hormone 1-84, rhPTH (1-84)), suggesting that
the investigational therapy has a beneficial effect on bone health in patients
with hypoparathyroidism. According to NPS, investigators also reported
findings from the PARADOX burden of illness survey suggesting that patients
with hypoparathyroidism have a substantial burden of illness in the skeleton
and joints and experience bone-related symptoms and comorbidities despite
receiving standard care, such as calcium and active vitamin D. The Company
stated that the findings from REPLACE and PARADOX were presented in respective
poster sessions at the Annual Meeting of the American Society for Bone and
Mineral Research (ASBMR) in Baltimore, Maryland. The Full Research Report on
NPS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/441a_NPSP]

--

Incyte Corporation Research Report

On October 10, 2013, Incyte Corporation (Incyte) announced that it will
release its Q3 2013 results on Thursday, October 31, 2013 at 7:00 a.m. ET,
which will be followed by a conference call at 8:30 a.m. ET on the same day.
Incyte reported that interested parties may access a live webcast of the
conference call through its Investor Relations, Events, and Webcast sections
of the website. The Full Research Report on Incyte Corporation - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/076e_INCY]

--

Nektar Therapeutics Research Report

On October 8, 2013, Nektar Therapeutics (Nektar) presented an overview of its
proprietary drug candidate pipeline during the Company's R&D Day for investors
and analysts in New York City. According to Nektar, it presented data from two
Phase 2 studies of NKTR-181, the Company's novel mu-opioid analgesic molecule,
followed by new topline clinical data from an ongoing investigator-sponsored
Phase 2 study of Nektar's proprietary cancer drug candidate, NKTR-102, in
patients with Avastin-resistant high-grade glioma, as well as new
receptor-based research for NKTR-192, the Company's novel analgesic molecule
for acute pain that is currently in Phase 1 development. Howard W. Robin,
President and CEO of Nektar, said, "Nektar has one of the most exciting and
robust pipelines in the biotech industry. In addition to our four partnered
programs, which are in or have completed Phase 3 studies, we have a deep
proprietary pipeline of novel therapeutic candidates." The Full Research
Report on Nektar Therapeutics - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/3421_NKTR]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement